{"id":8989,"date":"2020-08-11T11:09:00","date_gmt":"2020-08-11T18:09:00","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=8989"},"modified":"2021-04-13T11:09:41","modified_gmt":"2021-04-13T18:09:41","slug":"immunogenicity-and-safety-of-a-sars-cov-2-inactivated-vaccine-in-healthy-adults-aged-18-59-years-report-of-the-randomized-double-blind-and-placebo-controlled-phase-2-clinical-trial","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/08\/11\/immunogenicity-and-safety-of-a-sars-cov-2-inactivated-vaccine-in-healthy-adults-aged-18-59-years-report-of-the-randomized-double-blind-and-placebo-controlled-phase-2-clinical-trial\/","title":{"rendered":"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years Report of the Randomized Double-Blind and Placebo-Controlled Phase 2 Clinical Trial"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"34\" data-aria-posinset=\"2019\" data-aria-level=\"1\"><i><span data-contrast=\"none\">[pre-print, not peer-reviewed]<\/span><\/i><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">Zhang<\/span><span data-contrast=\"auto\">\u00a0et al. conducted a randomized, double-blind, placebo-controlled trial to evaluate the optimal dose, immunogenicity<\/span><span data-contrast=\"auto\">,<\/span><span data-contrast=\"auto\">\u00a0and safety of\u00a0<\/span><span data-contrast=\"auto\">a SARS-CoV-2 inactivated\u00a0<\/span><span data-contrast=\"auto\">whole virion\u00a0<\/span><span data-contrast=\"auto\">vaccine (<\/span><span data-contrast=\"auto\">CoronaVac<\/span><span data-contrast=\"auto\">),<\/span><span data-contrast=\"auto\">\u00a0finding that\u00a0<\/span><span data-contrast=\"auto\">the vaccine demonstrated\u00a0<\/span><span data-contrast=\"auto\">favorable safety and immunogenicity on both schedules and both dosages.<\/span><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">T<\/span><span data-contrast=\"auto\">he lower 3 g dose elicit<\/span><span data-contrast=\"auto\">ed<\/span><span data-contrast=\"auto\">\u00a092.4% seroconversion under\u00a0<\/span><span data-contrast=\"auto\">a\u00a0<\/span><span data-contrast=\"auto\">Day 0,<\/span><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">14 schedule and 97.4% under\u00a0<\/span><span data-contrast=\"auto\">a\u00a0<\/span><span data-contrast=\"auto\">Day 0,<\/span><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">28\u00a0<\/span><span data-contrast=\"auto\">schedule<\/span><span data-contrast=\"auto\">.\u00a0<\/span><span data-contrast=\"auto\">Most adverse events were\u00a0<\/span><span data-contrast=\"auto\">mild<\/span><span data-contrast=\"auto\">\u00a0and the three serious adverse events were determined to be unrelated to the vaccine<\/span><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"none\">Zhang et al. (Aug 10, 2020). Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years Report of the Randomized Double-Blind and Placebo-Controlled Phase 2 Clinical Trial.\u00a0<\/span><\/i><i><span data-contrast=\"none\">Pre-print downloaded Aug 11 from<\/span><\/i><i><span data-contrast=\"none\">\u00a0<\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2020.07.31.20161216\"><span data-contrast=\"none\">https:\/\/doi.org\/10.1101\/2020.07.31.20161216<\/span><\/a><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;335559685&quot;:720}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[pre-print, not peer-reviewed]\u00a0Zhang\u00a0et al. conducted a randomized, double-blind, placebo-controlled trial to evaluate the optimal dose, immunogenicity,\u00a0and safety of\u00a0a SARS-CoV-2 inactivated\u00a0whole virion\u00a0vaccine (CoronaVac),\u00a0finding that\u00a0the vaccine demonstrated\u00a0favorable safety and immunogenicity on both schedules and both dosages.\u00a0The lower 3 g dose elicited\u00a092.4% seroconversion under\u00a0a\u00a0Day 0,\u00a014 schedule and 97.4% under\u00a0a\u00a0Day 0,\u00a028\u00a0schedule.\u00a0Most adverse events were\u00a0mild\u00a0and the three serious adverse events&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/08\/11\/immunogenicity-and-safety-of-a-sars-cov-2-inactivated-vaccine-in-healthy-adults-aged-18-59-years-report-of-the-randomized-double-blind-and-placebo-controlled-phase-2-clinical-trial\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[31],"class_list":["post-8989","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=8989"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8989\/revisions"}],"predecessor-version":[{"id":8990,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8989\/revisions\/8990"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=8989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=8989"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=8989"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=8989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}